Cardiology

Results from the MITHRAS trial reported at TCT Connect

The MITHRAS randomized clinical trial found that interventional closure of an iatrogenic atrial septal defect (iASD) driven by transcatheter mitral valve repair (TMVR) was not superior to conservative medical treatment with ...

Oncology & Cancer

Halting cancer by halting DNA repair

PARP inhibitors are rapidly transforming the treatment of ovarian, breast, prostate and other types of cancer. To develop these drugs, researchers supported by Cancer Research UK had to decipher how blocking DNA repair could ...

Oncology & Cancer

Breast cancer drug set to transform prostate cancer treatment

A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Medical research

Building bridges: PARP enzymes bring broken DNA together

Scientists at St. Jude Children's Research Hospital have identified the structure of double-strand DNA break repair by PARP enzymes. The findings show that PARP2 can bridge the gap, bringing two broken DNA ends together.

page 1 from 61